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ABSTRACT
Objective: The present study was aimed to assess the antifungal activity of Tinospora cordifolia aqueous extract (TCAE) against Aspergillus fumigatus 
infection.
Methods: TCAE was tested for in vitro antifungal activity against the isolates of A. fumigatus, Aspergillus flavus, and Aspergillus niger. To evaluate 
in vivo activity, various doses (10, 25, and 50 mg/kg) of TCAE were orally administered in A. fumigatus-infected mice for 7 days. The combination of 
prophylactic and therapeutic effect of TCAE was assessed by pre-treating the mice with 10 mg/kg of TCAE for 3 consecutive days before exposing them 
to A. fumigatus. Mice were treated with 10, 25, and 50 mg/kg doses of TCAE for 7 consecutive days’ post-A. fumigatus infection. The effectiveness of 
TCAE was evaluated by monitoring the survival rate and assessing the fungal burden in the kidney of the treated mice.
Results: A. fumigatus-infected mice treated with TCAE at the doses of 25 and 50 mg/kg exhibited 50% and 20% survival rate, respectively, observed 
on day 40 post-treatment. Like to the survival data, the fungal burden was also found to be the lowest in the kidney of mice treated with TCAE at a dose 
of 50 mg/kg. The results showed that pre-treatment with TCAE (10 mg/kg) followed by post-infection treatment with 10, 25, and 50 mg/kg of TCAE 
for 7 days resulted in 40%, 50%, and 70% survival rate, respectively.
Conclusions: These results suggest that TCAE may potentially be considered for its possible use in the treatment of the systemic infection of 
A. fumigatus.
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INTRODUCTION
The therapeutic use of antibiotics has played a tremendous role in 
combating various infectious diseases [1]. Although the indiscriminate 
and extensive use of antifungals has resulted in the emergence of 
multidrug-resistant isolates of fungal pathogens, which are posing 
serious challenges to the clinicians [2]. Moreover, some antifungal 
agents, particularly polyene antibiotics, have been shown to exert 
serious untoward effects [3,4]. As there are limited numbers of 
antifungals available in the market, it is important to find suitable 
replacements for some of the currently used antifungals [5].
Giloy, Tinospora cordifolia, has been used for centuries in the Ayurvedic 
and Unani Systems of the Medicine for the treatment of ailments. 
It has been demonstrated to have antidiabetic, antioxidant, anti-
hepatotoxic, and immunomodulatory properties [6-8]. The aqueous 
extract of T. cordifolia has been shown to protect against Escherichia 
coli and Staphylococcus aureus infections [9,10]. The active ingredient, 
G 1-4A, of T. cordifolia stem protected mice against lipopolysaccharide-
induced endotoxic shock [11]. It also controlled the drug-resistance 
Mycobacterium tuberculosis by modulating the immune responses [12]. 
Recently, we showed that aqueous and methanolic extracts of T. cordifolia 
alleviated the Salmonella typhimurium infection in a mouse model [13].
Invasive aspergillosis (IA) caused by Aspergillus fumigatus is a major cause 
of mortality in immunocompromised persons, including patients with 
leukemia, undergoing bone marrow, and solid organ transplantation [14]. 
Treatment of fungal infections has been a challenge for clinicians due 
to the limited number of antifungals currently available in the market. 
Recent upsurge in the frequency of azole-resistant A. fumigatus isolates 
has further limited our antifungal armory. On the other hand, polyene 
antifungals have been shown to exert an acute renal toxicity in the treated 
subjects. Thus, it is important to find a plant-derived broad-spectrum 
antifungal agents that can be used to treat infectious fungal diseases. In 
the present study, we used T. cordifolia aqueous extract (TCAE) against 
A. fumigatus both in vitro and in a mouse model. The results of the 
present study demonstrated that TCAE effectively alleviated the systemic 
infection of A. fumigatus in the mouse model.
MATERIALS AND METHODS
Materials
Sabouraud Dextrose Agar (SDA) was purchased from HiMedia Pvt. Ltd. 
Mumbai, India. Amphotericin B was purchased from Sigma-Aldrich (St. 
Louis, Mo, USA).
Mice
BALB/C mice of 10–12 weeks of age were used in this study. Mice 
were purchased from the animal house facility of King Saud University, 
Riyadh, Saudi Arabia. The techniques used for bleeding, injection, and 
sacrifice of animals were approved by an Animal Ethics Committee of 
the College of Applied Medical Sciences, Qassim University, Buraydah.
Preparation of extracts from the stems of T. cordifolia
The dried stems of T. cordifolia were procured from the registered 
attar shop in Buraydah, Saudi Arabia. The plant was identified by 
Dr. Masihuzzama Khan, Assistant Professor in the Department of 
Pharmacognosy, Unaizah College of Pharmacy, Unaizah, Qassim 
University. The stems were powdered and TCAE was prepared as 
described previously [13].
Determination of the antifungal activity
The antifungal activity of TCAE was determined using the agar well 
diffusion method [13]. Wells (8-mm diameter) were punched in the 
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agar. TCAE was dispensed in different wells (20 mg/ml) and incubated 
at 37°C for 24 h. The antifungal activity of TCAE was assessed by 
measuring the zone of inhibition. The wells containing amphotericin B 
(10 mg/ml) and saline were considered as positive and negative 
controls, respectively.
Preparation of A. fumigatus for infection
A. fumigatus was cultured as described in the previous section. Each 
mouse was infected through the intravenous route with a lethal dose of 
7 × 105 viable A. fumigatus spores [14].
Treatment of A. fumigatus-infected mice with AETC
Mice were treated with various doses (10, 25, and 50 mg/kg) 
of TCAE orally for 7 days (day 1–7) after A. fumigatus infection 
(day 0). Mice were divided into the following groups: (1) Saline, 
(2) TCAE - 10 mg/kg, (3) TCAE - 25 mg/kg, and (4) TCAE - 50 mg/kg. Each 
group was comprised of 10 mice.
Prophylactic use of TCAE against A. fumigatus
To determine the prophylactic effect of TCAE against A. fumigatus, mice 
were pre-treated (PT) for 3 consecutive days (−3–−1 days) with a dose 
of 10 mg/kg of AETC. On day 0, mice were infected with 7×105 viable 
A. fumigatus spores through intravenous route. Treatment with 200 µl of 
10, 25, and 50 mg/kg of doses of TCAE was given for 7 days to A. fumigatus-
infected mice that were prophylactically treated or untreated with TCAE 
(10 mg/kg). Mice were divided into following groups: (1) Saline, (2) PT 
+ TCAE - 10 mg/kg, (3) TCAE - 10 mg/kg, (4) PT + TCAE - 10 mg/kg + 
TCAE - 10 mg/kg, (5) TCAE - 25 mg/kg, (6) PT + TCAE - 10 mg/kg + 
TCAE - 25 mg/kg, (7) TCAE - 50 mg/kg, and (8) PT + TCAE - 10 mg/kg 
+ TCAE - 50 mg/kg.
Quantitative analysis of A. fumigatus in the kidney
The severity of A. fumigatus infection was assessed by determining 
the fungal load in the kidney of mice untreated or treated with 
T. cordifolia extract. Three mice from each group were sacrificed on 
day 3 post-A. fumigatus infection, and their kidneys were taken out 
aseptically as described earlier [14]. Briefly, weighed portions of the 
kidney tissues were homogenized in 5 ml of sterile normal saline, 
and different dilutions of the suspension were plated on SDA plates. 
The plates were incubated at 37°C for 48 h. The numbers of viable A. 
fumigatus colonies were counted and the fungal load was determined 
by multiplying by the dilution factor.
Statistical analyses
Analysis of the survival of mice was performed using Kaplan–Meier 
curve, and various groups were compared by the log-rank test. Fungal 
burden (colony-forming units [CFU]) in the kidney was analyzed by 
one-way ANOVA using GraphPad Prism software version 5.0.
RESULTS
The aqueous extract of T. cordifolia shows in vitro antifungal activity
The aqueous extract of T. cordifolia showed potent activity against 
A. fumigatus, Aspergillus Flavus, and Aspergillus niger used in the study. 
A zone of inhibition was calculated as the percentage antifungal activity 
of amphotericin B (100%). Table 1 shows that T. cordifolia extracts 
showed the antifungal activity against all three strains of Aspergillus.
Treatment with TCAE results in increased survival of 
A. fumigatus-infected mice
The therapeutic effect of TCAE was determined by treating A. 
fumigatus-infected mice with the doses of 10, 25, and 50 mg/kg of 
TCAE for 7 consecutive days. Mice were observed for 40 days for their 
survival. All A. fumigatus-infected mice in the untreated group died by 
day 10. A. fumigatus-infected mice in the groups treated with 25 and 
50 mg/kg of TCAE showed 30% and 40% survival, respectively (Fig. 1). 
The survival rate of mice in the group treated with TCAE at a dose of 
50 mg/kg was found to be significantly greater as compared to that of 
mice in the untreated group (p<0.01).
Mice treated with TCAE showed more resistance against 
A. fumigatus infection
The severity of A. fumigatus infection was determined by culturing 
the tissue homogenates of kidneys of the A. fumigatus-infected 
mice treated or untreated with TCAE. There were higher CFUs of 
A. fumigatus in the kidneys of untreated mice (Fig. 2). Mice treated 
with 50 mg/kg of TCAE showed least CFUs in their kidney tissue 
homogenates (Fig. 2).
Prophylactic use of TCAE increases the therapeutic efficacy of the 
same formulation in combating A. fumigatus infection in mice
The combination of prophylactic and therapeutic effect of TCAE 
was assessed by pre-treating the mice with 10 mg/kg of TCAE for 
3 consecutive days before challenging them with A. fumigatus. Mice 
were treated with three doses (10, 25, and 50 mg/kg) of TCAE for 
7 consecutive days’ post-A. fumigatus infection as described in the 
methods section. The results showed that pre-treatment with TCAE 
(10 mg/kg) followed by post-infection treatment with 10, 25, and 
50 mg/kg of TCAE for 7 days resulted in 40%, 50%, and 70% survival, 
respectively, on day 40 (Fig. 3). The mice that received only TCAE pre-
treatment also showed increased survival compared to untreated mice 
(Fig. 3).
The assessment of the severity of Aspergillosis in the group of 
immunocompetent mice pre-treated with TCAE showed much reduced 
fungal loads in their kidneys compared to mice in other groups. Mice that 
were only PT with TCAE also resisted A. fumigatus infection as shown 
by lower fungal load in their kidneys compared to mice not receiving 
any TCAE pretreatment (Fig. 4). The group of immunocompetent mice 
pre-treated with TCAE followed by treatment with 50 mg/kg of TCAE 
showed the least CFU counts in their kidneys (Fig. 4).
Table 1: The antifungal activity of TCAE





The data represent mean of three different experiments±S.D, TCAE: Tinospora 
cordifolia aqueous extract
Fig. 1: Tinospora cordifolia aqueous extract (TCAE) increases 
the survival of the Aspergillus fumigatus-infected mice. Mice 
were infected with 7×105 colony-forming units of A. fumigatus 
through intravenous route. Treatment with the doses of 10, 25, 
and 50 mg/kg of TCAE was given for consecutive 7 days’ post-
infection. Mice were observed for 40 days for their survival; saline 
(■), TCAE - 10 mg/kg (▲), TCAE - 25 mg/kg (♦), TCAE - 50 mg/kg 
(●). Untreated control versus TCAE - 50 mg/kg (p<0.01)
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DISCUSSION
In the recent years, the antibiotic resistance ability of A. fumigatus 
has contributed to increased frequency of Aspergillosis in human 
population [15]. The use of plants and their bioactive constituents has 
emerged as a promising alternative to traditional drugs in the treatment 
of fungal infections [16]. We have earlier shown that thymoquinone, a 
major bioactive constituent of Nigella sativa seeds, possesses a strong 
activity against Candida albicans in a mouse model [16]. Due to the 
problem of antibiotic resistance and prevalence of immune suppression, 
the treatment of Aspergillosis is posing a big threat to human society. 
Plant-derived antifungal agents can selectively act on various targets 
with fewer side effects. Since there are less chances of fungal resistance 
against herbal preparations due to their multiple mechanisms of action, 
the use of medicinal plants may be proved a better option for the 
treatment of drug-resistant Aspergillosis.
In the present study, the aqueous extract of T. cordifolia showed its 
activity against different Aspergillus spp. including A. fumigatus, 
A. flavus, and A. niger. TCAE was tested against A. fumigatus, A. flavus, 
and A. niger in in vitro studies and was effective in inhibiting the growth 
of these fungi. This encouraged us to use TCAE against A. fumigatus in 
a murine model. Interestingly, the result of in vivo studies confirmed 
the activity of TCAE against A. fumigatus. A. fumigatus-infected mice 
showed increased survival and less fungal load in their kidney tissues 
after treatment with TCAE, particularly at higher doses.
T. cordifolia and its constituents have been shown to possess 
immunostimulating activities [13]. An α-D-glucan, a constituent found 
in T. cordifolia, has shown its efficacy in stimulating NK cells, B cells, and 
T cells with simultaneous production of various immune-stimulatory 
cytokines. This stimulation of immune cells can play a very crucial role 
in combating the fungal infectious diseases. We have recently shown 
that both aqueous and methanolic extracts of T. cordifolia stimulate the 
secretion of important cytokines by macrophages that contribute to the 
elimination of S. typhimurium infection from mice [13]. The immune-
stimulating effect of T. cordifolia is also evident from the results of 
Fig. 2: Treatment with Tinospora cordifolia aqueous extract (TCAE) 
reduces the fungal burden in the kidney of Aspergillus fumigatus-
infected mice. Mice were infected with 7×105 colony-forming units 
of A. fumigatus through intravenous route. Treatment with various 
doses (10, 25, and 50 mg/kg) of TCAE was given for consecutive 
7 days’ post-A. fumigatus infection. On day 3 post-A. fumigatus 
infection, three mice from each untreated or treated group were 
sacrificed and the kidneys were taken out for homogenization. 
The kidney tissue homogenates were cultured to determine the 
fungal burden. Untreated control versus TCAE-50 mg/kg (p<0.01), 
untreated control versus TCAE-25 mg/kg (p<0.05)
Fig. 3: The combination of prophylactic and therapeutic use of 
Tinospora cordifolia aqueous extract (TCAE) was more effective 
in the treatment of Aspergillus fumigatus infection in mice. Mice 
were pre-treated with a dose of 10 mg/kg of TCAE for consecutive 
3 days. After pre-treatment with TCAE, mice were infected with 
7×105 colony-forming units of A. fumigatus through intravenous 
route. Treatment with various doses (10, 25, and 50 mg/kg) of 
TCAE was given for consecutive 7 days’ post-infection. Mice were 
observed for 40 days to monitor their mortality and morbidity. 
Saline (■), TCAE - 10 mg/kg (▲), PT + TCAE - 10 mg/kg (□), 
PT + TCAE - 10 mg/kg + TCAE - 10 mg/kg (∆), TCAE - 25 mg/kg (♦), 
PT + TCAE - 10 mg/kg + TCAE - 25 mg/kg (◊), TCAE - 25 mg/kg (○), 
PT + TCAE - 10 mg/kg + TCAE - 25 mg/kg (■). Untreated control 
versus PT-TCAE + TCAE - 25 mg/kg (P<0.05), Untreated control 
versus TCAE-50 mg/kg (p<0.05), untreated control versus PT-
TCAE + TCAE-50 mg/kg (p<0.01)
Fig. 4: Prophylactic treatment with Tinospora cordifolia 
aqueous extract (TCAE) increases the therapeutic efficacy of 
the same formulation against Aspergillus fumigatus. Mice were 
PT with a dose of 10 mg/kg of TCAE for consecutive 3 days. 
After pre-treatment with TCAE, mice were infected with 7×105 
CFU of A. fumigatus through intravenous route. Treatment 
with various doses (10, 25, and 50 mg/kg) of TCAE was 
given for consecutive 7 days’ post-infection. On day 3 post-A. 
fumigatus infection, three mice from each untreated or treated 
group were sacrificed and the kidneys were taken out for 
homogenization. The kidney tissue homogenates were cultured 
to determine fungal burden. Untreated control versus PT-TCAE 
+ TCAE - 50 mg/kg (p<0.05), untreated control versus PT-TCAE 
+ TCAE - 25 mg/kg (p<0.01), untreated control versus 
TCAE - 50 mg/kg (p<0.05), untreated control versus PT - TCAE + 
TCAE - 50 mg/kg (p<0.001)
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our in vivo studies as the combination of prophylactic and therapeutic 
use of TCAE was most effective against A. fumigatus. Thus, the use of 
T. cordifolia extracts for the treatment of Aspergillosis seems to have 
superiority over commonly used antibiotics as earlier possesses both 
immunostimulatory and antifungal activities.
Extensive use of antibiotics causes systemic toxicity and immune 
suppression in the treated patients and predisposes them to 
opportunistic bacterial and fungal infections. The use of herbal 
medicine minimizes the chances of toxicity, which may support its 
use for extended periods. Although more extensive studies are needed 
before considering T. cordifolia as an attractive and safe option in the 
treatment for Aspergillosis. Furthermore, this preparation may also 
be studied for its implications to treat other opportunistic infections 
in immunocompromised persons due to its immunopotentiating 
properties.
CONCLUSIONS
The results of the present study suggest that some bioactive constituents 
present in TCAE may be responsible for its activity against A. fumigatus. 
It is essential that further study should be continued to isolate and 
purify the bioactive components of T. cordifolia that are responsible for 
antifungal activity.
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